Title
Hereditary Angioedema, Acquired C1 Inhibitor Deficiency, and Angiotensin-Converting Enzyme Inhibitor–Associated Angioedema
Authoring Organizations
Publication Month/Year
June 1, 2013
Last Updated Month/Year
October 17, 2024
Supplemental Implementation Tools
Document Type
Guideline
External Publication Status
Published
Country of Publication
US
Document Objectives
In 2013, the United States Hereditary Angioedema Association Medical Advisory Board (US HAEA MAB) published recommendations for the management of hereditary angioedema (HAE) due to C1 inhibitor (C1INH) deficiency (HAE-C1INH). This document builds upon the 2013 paper, updating and expanding those recommendations to reflect the rapid progress during the intervening years and incorporating recommendations for HAE with normal C1INH (HAE-nl-C1INH).
Target Patient Population
Patients with hereditary angioedema (HAE)
Inclusion Criteria
Male, Female, Adolescent, Adult, Child, Infant, Older adult
Health Care Settings
Ambulatory, Outpatient
Intended Users
Nurse, nurse practitioner, physician, physician assistant
Scope
Diagnosis, Treatment, Management, Prevention
Diseases/Conditions (MeSH)
D054179 - Angioedemas, Hereditary, D056828 - Hereditary Angioedema Type III, D056829 - Hereditary Angioedema Types I and II
Keywords
angioedema, hereditary angioedema, HAE, acquired C1 inhibitor deficiency, C1 Inhibitor Deficiency, C1INH deficiency
Source Citation
Busse PJ, Christiansen SC, Riedl MA, Banerji A, Bernstein JA, Castaldo AJ, Craig T, Davis-Lorton M, Frank MM, Li HH, Lumry WR, Zuraw BL. US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema. J Allergy Clin Immunol Pract. 2021 Jan;9(1):132-150.e3. doi: 10.1016/j.jaip.2020.08.046. Epub 2020 Sep 6. PMID: 32898710.